Page 115 - 醫研部6月份電子報

“My impression at the time was that so many of these children died, and I

would not enjoy working in such a specialty,” she said. “However, by the time I

had my residency, we were starting to see rising rates of survival in leukemia [in

pediatric patients], and I thought maybe this field holds promise.”

With the advances in survival and the introduction of therapies for

neuroblastoma and other childhood cancers that she has seen in the ensuing

years, Dr. Yu said she is now happy about her career choice. “It’s an exciting

field,” she said. “I’m glad I chose it, even though I didn’t think so early on.”

References

1. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF,

interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med .

2010;363(14):1324-1334.

2. Ozkaynak MF, Gilman AL, London WB, et al. A comprehensive safety trial of

chimeric antibody 14.18 with GM-CSF, IL-2, and isotretinoin in high-risk

neuroblastoma patients following myeloablative therapy: Children's

Oncology Group Study ANBL0931. Front Immunol . 2018 Jun 18;9:1355.

3. Mody R, Naranjo A, Van Ryn C, et al. Irinotecan-temozolomide with

temsirolimus or dinutuximab in children with refractory or relapsed

neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2

trial. Lancet Oncol . 2017;18(7):946-957.

Department of Medical Research & Development, Linkou Newsletter 115